Cancer-related inflammation and treatment effectiveness

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Roxburgh, 2012, The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer, Cancer Treat Rev, 38, 451, 10.1016/j.ctrv.2011.09.001 Mei, 2014, Tumour-infiltrating inflammation and prognosis in colorectal cancer: systemic review and meta-analysis, Br J Cancer, 110, 1595, 10.1038/bjc.2014.46 McMillan, 2013, The systemic inflammation-based Glasgow prognosis score: a decade of experience in patients with cancer, Cancer Treat Rev, 39, 534, 10.1016/j.ctrv.2012.08.003 Guthrie, 2013, The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer, Crit Rev Oncol Hematol, 88, 218, 10.1016/j.critrevonc.2013.03.010 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Richards, 2011, The prognostic value of histological tumour necrosis in solid organ malignant disease: a systematic review, Future Oncol, 7, 1223, 10.2217/fon.11.99 Frank, 2002, An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumour stage, size, grade and necrosis: the SSIGN score, J Urol, 168, 2395, 10.1016/S0022-5347(05)64153-5 Fisher, 1978, Pathological findings from the national surgical adjuvant breast project (protocol no. 4). IV. Signficance of tumour necrosis, Hum Pathol, 9, 523, 10.1016/S0046-8177(78)80133-6 Richards, 2012, Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer, Br J Surg, 99, 287, 10.1002/bjs.7755 Kolb, 2014, Inflammasomes in cancer: a double-edged sword, Protein Cell, 5, 12, 10.1007/s13238-013-0001-4 Henao-Mejia, 2012, Inflammasomes: far beyond inflammation, Nature Immunol, 13, 321, 10.1038/ni.2257 Terlizzi, 2014, Inflammasome: cancer's friend or foe?, Pharmacol Ther, 143, 24, 10.1016/j.pharmthera.2014.02.002 Tu, 2008, Overexpression of interleukin-1b induces gastric inflammation and cancer and mobilises myeloid-derived suppressor cells in mice, Cancer Cell, 14, 408, 10.1016/j.ccr.2008.10.011 Terme, 2011, IL-18 induces PD-1-dependent immunosuppression in cancer, Cancer Res, 71, 5393, 10.1158/0008-5472.CAN-11-0993 Palma, 2013, Interleukin 18: friend or foe in cancer, Biochim Biophys Acta, 1836, 296 Germano, 2008, Cytokines as a key component of cancer-related inflammation, Cytokine, 43, 374, 10.1016/j.cyto.2008.07.014 Gabrilovich, 2012, Coordinated regulation of myeloid cells by tumours, Nat Rev Immunol, 12, 253, 10.1038/nri3175 Larrivée, 2005, Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor, J Immunol, 175, 3015, 10.4049/jimmunol.175.5.3015 Morishima, 2011, Neutrophil differentiation from human-induced pluripotent stem cells, J Cell Physiol, 226, 1283, 10.1002/jcp.22456 Guthrie, 2013, Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?, Cancer Treat Rev, 39, 89, 10.1016/j.ctrv.2012.07.003 Richards, 2012, The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer, Br J Cancer, 106, 2010, 10.1038/bjc.2012.211 Mohammed, 2012, The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer, Br J Cancer, 107, 864, 10.1038/bjc.2012.347 Putoczki, 2013, Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically, Cancer Cell, 24, 257, 10.1016/j.ccr.2013.06.017 Taniguchi, 2014, IL-6 and related cytokines as the critical lynchpins between inflammation and cancer, Semin Immunol, 26, 54, 10.1016/j.smim.2014.01.001 DiDonato, 2012, NF-kB and the link between inflammation and cancer, Immunol Rev, 246, 379, 10.1111/j.1600-065X.2012.01099.x Grivennikov, 2009, Inflammation and oncogenesis: a vicious connection, Curr Opin Genet Dev, 20, 65, 10.1016/j.gde.2009.11.004 Klintrup, 2005, Inflammation and prognosis in colorectal cancer, Eur J Cancer, 41, 2645, 10.1016/j.ejca.2005.07.017 Galon, 2006, Type, density and location of immune cells within human colorectal tumours predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Michael-Robinson, 2001, Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status, Gut, 48, 360, 10.1136/gut.48.3.360 Park, 2014, The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer, Ann Oncol, 25, 644, 10.1093/annonc/mdt593 Mandruzzato, 2009, IL4Ra+ myeloid-derived suppressor cell expansion in cancer patients, J Immunol, 182, 6562, 10.4049/jimmunol.0803831 Laird, 2013, The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer, Oncologist, 18, 1050, 10.1634/theoncologist.2013-0120 Iida, 2013, Commensal bacterial control cancer response to therapy by modulating the tumour microenvironment, Science, 342, 967, 10.1126/science.1240527 Viaud, 2013, The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide, Science, 342, 971, 10.1126/science.1240537 Heikkila, 2007, A systematic review of the association between circulating concentrations of C reactive protein and cancer, J Epidemiol Community Health, 61, 824, 10.1136/jech.2006.051292 Tsilidis, 2008, C-reactive protein and colorectal cancer risk: a systematic review of prospective studies, Int J Cancer, 123, 1133, 10.1002/ijc.23606 Beer, 2008, C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer, Cancer, 112, 2377, 10.1002/cncr.23461 Saito, 2011, C-reactive proteins as a biomarker for urological cancers, Nat Rev Urol, 8, 659, 10.1038/nrurol.2011.145 Roxburgh, 2011, Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors, Int J Colorectal Dis, 26, 483, 10.1007/s00384-010-1120-5 Michael, 2006, Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count, Clin Colorectal Cancer, 6, 297, 10.3816/CCC.2006.n.048 Chua, 2011, Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer, Br J Cancer, 104, 1288, 10.1038/bjc.2011.100 Kao, 2010, High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy, Clin Cancer Res, 16, 5805, 10.1158/1078-0432.CCR-10-2245 Leitch, 2007, Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer, Br J Cancer, 97, 1266, 10.1038/sj.bjc.6604027 Shi, 2011, Monocyte recruitment during infection and inflammation, Nat Rev Immunol, 11, 762, 10.1038/nri3070 Peranzoni, 2010, Myeloid-derived suppressor cell heterogeneity and subset definition, Curr Opin Immunol, 22, 238, 10.1016/j.coi.2010.01.021 Ohki, 2012, Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer, Oncol Rep, 28, 453, 10.3892/or.2012.1812 Diaz-Montero, 2009, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumour burden, and doxocubicin-cyclophosphamide chemotherapy, Cancer Immunol Immunother, 58, 49, 10.1007/s00262-008-0523-4 Tel, 2014, Tumoricidal activity of human dendritic cells, Trends Immunol, 35, 38, 10.1016/j.it.2013.10.007 Proctor, 2011, A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome study, Eur J Cancer, 47, 2633, 10.1016/j.ejca.2011.03.028 MacDonald, 2012, Terminology in cancer cachexia: importance and status, Curr Opin Nutr Metab, 15, 220, 10.1097/MCO.0b013e328352a895 Slaviero, 2003, Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy, Lancet Oncol, 4, 224, 10.1016/S1470-2045(03)01034-9 Alexandre, 2003, Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy, Ann Oncol, 14, 36, 10.1093/annonc/mdg013 Roxburgh, 2014, Cancer and systemic inflammation: treat the tumour and treat the host, Br J Cancer, 110, 1409, 10.1038/bjc.2014.90 Chan, 2013, An emerging role for anti-inflammatory agents for chemoprevention, 1 Solheim, 2013, Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review, Acta Oncol, 52, 6, 10.3109/0284186X.2012.724536 Forget, 2013, Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung and kidney cancer surgery, Ann Surg Oncol, 20, S650, 10.1245/s10434-013-3136-x Rothwell, 2012, Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials, Lancet, 379, 1591, 10.1016/S0140-6736(12)60209-8 Chia, 2012, Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms, Nat Rev Clin Oncol, 9, 561, 10.1038/nrclinonc.2012.137 Liao, 2012, Aspirin use, tumour PIK3CA mutation, and colorectal-cancer survival, N Engl J Med, 367, 1596, 10.1056/NEJMoa1207756 Seufert, 2013, IkBKb and NFkB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry, Carcinogenesis, 34, 79, 10.1093/carcin/bgs296 Lonnroth, 2008, Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumour tissue infiltration of seemingly activated immune cells in colorectal cancer, Cancer Immun, 8, 5 Leggas, 2009, Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy, Cancer Chemother Pharmacol, 63, 731, 10.1007/s00280-008-0767-x Bonovas, 2007, Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients, J Clin Oncol, 25, 3462, 10.1200/JCO.2007.10.8936 Samadder, 2011, Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk of statin and NSAID use, Cancer, 117, 1640, 10.1002/cncr.25731 Jain, 2005, Anti-inflammatory effects of statins: clinical evidence and basic mechanisms, Nat Rev Drug Discov, 4, 977, 10.1038/nrd1901 Kwak, 2000, Statins as a newly recognised type of immunomodulator, Nat Med, 6, 1399, 10.1038/82219 Mbeunki, 2009, Cancer and the tumour microenvironment: a review of an essential relationship, Cancer Chemother Pharmacol, 63, 571, 10.1007/s00280-008-0881-9 Trikha, 2003, Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence, Clin Cancer Res, 9, 4653 Cowards, 2011, Interleukin-6 as a therapeutic target in human ovarian cancer, Clin Cancer Res, 17, 6083, 10.1158/1078-0432.CCR-11-0945 Ando, 2013, Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia, J Clin Oncol, 31, e69, 10.1200/JCO.2012.44.2020 Brown, 2008, A clinical study assessing the tolerability and biological effects of infliximab, a TNF-a inhibitor, in patients with advanced cancer, Ann Oncol, 19, 1340, 10.1093/annonc/mdn054 Germano, 2011, Targeting of the innate immunity/inflammation as complementary anti-tumour therapies, Ann Med, 43, 581, 10.3109/07853890.2011.595732 Onuffer, 2002, Chemokines, chemokine receptors and small-molecule antagonists: recent developments, Trends Pharmacol Sci, 23, 459, 10.1016/S0165-6147(02)02064-3 Ryan, 2013, The past, present and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma, Am Soc Clin Oncol Educ Book, 386, 10.1200/EdBook_AM.2013.33.e386 Germano, 2013, Role of macrophage targeting in the antitumour activity of trabectedin, Cancer Cell, 23, 249, 10.1016/j.ccr.2013.01.008 Dieci, 2013, Fibroblast growth factor receptor inhibitors as a cancer treatment: from biological rationale to medical perspectives, Cancer Discov, 3, 264, 10.1158/2159-8290.CD-12-0362 Konstantinopoulos, 2011, Seeing the future of cancer-associated transcription factor drug targets, JAMA, 305, 2349, 10.1001/jama.2011.727 Fagard, 2013, STAT3 inhibitors for cancer therapy. Have all roads been explored?, JAKSTAT, 2, e22882 Mesa, 2013, Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomised, double-blind, placebo-controlled trial, J Clin Oncol, 31, 1285, 10.1200/JCO.2012.44.4489 Quintarelli, 2014, Selective strong synergism of ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia, Leuk Res, 38, 1285, 10.1016/j.leukres.2013.11.006 Tam, 2013, Investigational janus kinase inhibitors, Expert Opin Investig Drugs, 22, 687, 10.1517/13543784.2013.774373 Bosman, 2013, Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-kB and the accumulation of MCL-1, Exp Hematol, 41, 530, 10.1016/j.exphem.2013.02.002 Guo, 2013, Therapeutic cancer vaccines: past, present, and future, 421, 10.1016/B978-0-12-407190-2.00007-1 Pachucki, 2013, Dendritic-cell-based therapeutic cancer vaccines, Immunity, 39, 38, 10.1016/j.immuni.2013.07.004 Small, 2006, Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer, J Clin Oncol, 24, 3089, 10.1200/JCO.2005.04.5252 Aarntzen, 2012, Targeting CD4+ T-helper cells improves the induction of antitumour responses in dendritic cell-based vaccination, Cancer Res, 73, 19, 10.1158/0008-5472.CAN-12-1127 Terme, 2012, Modulation of immunity by antiangiogenic molecules in cancer, Clin Dev Immunol, 2012, 492920, 10.1155/2012/492920 Hodi, 2010, Improved survival with ipilumumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Kao, 2011, Targeting immune suppressing myeloid-derived suppressor cells in oncology, Crit Rev Oncol Hematol, 77, 12, 10.1016/j.critrevonc.2010.02.004 Pili, 2012, Phase II randomised, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer, J Clin Oncol, 29, 4022, 10.1200/JCO.2011.35.6295 Limaverde-Sousa, 2014, Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents, Cancer Treat Rev, 40, 548, 10.1016/j.ctrv.2013.11.009